What is Bunnell?
Bunnell Inc. is recognized for its advanced ventilation solutions, focusing on high-frequency jet ventilators designed for critically ill patients, with a particular emphasis on neonates. Their flagship products, the LifePulse 203 and 204 jet ventilators, are engineered to deliver superior physiologic impacts and therapeutic flexibility, establishing a benchmark in gentle infant ventilation. The company's dedication extends to clinical research and education within neonatal and pediatric care, offering healthcare professionals comprehensive training, resources, and support to ensure effective and user-friendly ventilation options for the most vulnerable infants.
How much funding has Bunnell raised?
Bunnell has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Bunnell
PPP
Public-Private Partnership
What's next for Bunnell?
The company's large-scale late-stage funding context suggests a strategic pivot towards significant market expansion, potential product line diversification, or substantial investment in research and development for next-generation ventilation technologies. This capital injection is likely to accelerate Bunnell's growth trajectory, enabling it to further solidify its market leadership and enhance its offerings in the critical care ventilation space. The focus on strategic investment indicates a clear path toward scaling operations and potentially exploring new therapeutic applications or geographical markets.
See full Bunnell company page
